A randomized phase II trial of interferon alpha-2A with and without 13-CIS retonoic acid [isotretinoin] in patients with progressive measurable metastatic renal cell carcinoma. Amendment Protocol: Extension to a Randomized Phase III Trial.

Trial Profile

A randomized phase II trial of interferon alpha-2A with and without 13-CIS retonoic acid [isotretinoin] in patients with progressive measurable metastatic renal cell carcinoma. Amendment Protocol: Extension to a Randomized Phase III Trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2012

At a glance

  • Drugs Interferon alpha-2a (Primary) ; Interferon alpha; Isotretinoin
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top